Kulangara et al. assessed the capacity of PD-L1 CPS and TPS as biomarkers to predict pembrolizumab potency in the KEYNOTE-059 trial, estimating pembrolizumab monotherapy and combination therapy in patients with recurrent or metastatic GC/GEJC [66]. The gene discussed is CD274; the disease is gastric cancer.